221 CRESCENT STREET, WALTHAM, MA
Viridian Therapeutics Enters Underwriting Agreement for $251.35M Offering
Company Expects Approximately $490.9 Million in Cash as of September 30, 2025
Viridian Therapeutics Enters $300 Million Purchase and Sale Agreement
Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
Viridian Therapeutics Partners with Kissei for Veligrotug and VRDN-003 in Japan, $70M Upfront, $315M Milestones
Changes in Board, Management or Compensation, Shareholder votes
Investor Presentation
Earnings Release
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
S-8 POS
Correspondence
Submission Upload